Gastrointestinal stromal tumors (GISTs) are malignant tumors arising from interstitial cells of cajal that can be located in any part of the digestive system.1 Their most common sites are the stomach and small intestine.2 Surgery either upfront or after preoperative treatment with tyrosine kinase inhibitors (TKIs) is still the most important treatment modality in GIST.2 In this issue of JAMA Surgery, Gronchi et al3 evaluate the association of microscopic radicality with patient outcomes. They use long-term data from a randomized clinical trial in which patients received TKI for 2 years or no adjuvant treatment after surgery to examine the association of R1 resection (no free margins) with recurrence and survival.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Almquist M, Nordenström E. R1 Resection in Gastrointestinal Stromal Tumors Is Not Worse Than R0. JAMA Surg. 2020;155(6):e200398. doi:10.1001/jamasurg.2020.0398
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: